Immunization with the BacMam-based IL-15:IL-15Rα cancer vaccine significantly delayed tumor growth by stimulating robust antitumor immune responses in tumor antigen-specific CD8+ T cells and NK cells while simultaneously attenuating Foxp3+ Treg cells. Here, FOXP3 is linked to neoplasm.